Adverse events and oncotargeted kinase inhibitors /
Saved in:
| Main Author: | |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Amsterdam :
Academic Press,
2017.
|
| Subjects: | |
| Online Access: | CONNECT |
Table of Contents:
- Front Cover; Adverse Events and Oncotargeted Kinase Inhibitors; Dedication; Adverse Events and Oncotargeted Kinase Inhibitors; Copyright; Contents; Acknowledgments; Acronyms; I
- General Aspects; 1
- Introduction; REFERENCES; 2
- Kinases; 2.1 PROTEIN KINASES; 2.1.1 Tyrosine Kinases; 2.1.1.1 Receptor Tyrosine Kinases; 2.1.1.2 Nonreceptor Tyrosine Kinases; 2.1.2 Serine/Threonine Kinases; 2.1.2.1 AGC; 2.1.2.2 Calcium/Calmodulin Dependent Kinase(s); 2.1.2.3 Casein Kinases; 2.1.2.4 CMGC; 2.1.3 STE Kinases; 2.1.4 Tyrosine-like Kinases; 2.1.5 Atypical Protein Kinases; 2.1.6 Other Kinases.
- 2.1.7 Additional Functional Grouping2.1.7.1 Receptor Serine/Threonine Kinases; 2.1.7.2 Serine/Threonine Kinases and Cell Cycle Control; 2.2 PROTEIN PHOSPHATASES AND DOWNREGULATION OF KINASES; REFERENCES; 3
- KINASE INHIBITORS; 3.1 KINASES AND MALIGNANCIES; 3.2 KINASE INHIBITORS; 3.3 ARE SAFETY ISSUES AN ACHILLES HEEL YET?; REFERENCES; 4
- Adverse Events; 4.1 CLASSIFICATION OF ADVERSE EVENTS; 4.2 SUBJECTIVITY AND OBJECTIVITY OF ADVERSE EVENT DOCUMENTATION; 4.3 NEW PRELIMINARY CRITERIA OF ADVERSE EVENT CLASSIFICATION AND EXPECTANCIES; REFERENCES; II
- Oncotargeted Kinase Inhibitors.
- 5
- Imatinib5.1 MECHANISM OF ACTION; 5.2 ADVERSE EVENTS; 5.3 OFF-LABEL EXPERIENCE; 5.4 POSTMARKETING SURVEILLANCE; 5.5 REMARKS; REFERENCES; 6
- GEFITINIB; 6.1 MECHANISM OF ACTION; 6.2 ADVERSE EVENTS; 6.3 OFF-LABEL EXPERIENCE; 6.4 POSTMARKETING SURVEILLANCE; 6.5 REMARKS; REFERENCES; 7
- Erlotinib; 7.1 MECHANISM OF ACTION; 7.2 ADVERSE EVENTS; 7.3 OFF-LABEL EXPERIENCE; 7.4 POSTMARKETING SURVEILLANCE; 7.5 REMARKS; REFERENCES; 8
- Sorafenib; 8.1 MECHANISM OF ACTION; 8.2 ADVERSE EVENTS; 8.3 OFF-LABEL EXPERIENCE; 8.4 POSTMARKETING SURVEILLANCE; 8.5 REMARKS; REFERENCES; 9
- Sunitinib.
- 9.1 MECHANISM OF ACTION9.2 ADVERSE EVENTS; 9.3 OFF-LABEL EXPERIENCE; 9.4 POSTMARKETING SURVEILLANCE; 9.5 REMARKS; REFERENCES; 10
- Dasatinib; 10.1 MECHANISM OF ACTION; 10.2 ADVERSE EVENTS; 10.3 OFF-LABEL EXPERIENCE; 10.4 POSTMARKETING SURVEILLANCE; 10.5 REMARKS; REFERENCES; 11
- Lapatinib; 11.1 MECHANISM OF ACTION; 11.2 ADVERSE EVENTS; 11.3 OFF-LABEL EXPERIENCE; 11.4 POSTMARKETING SURVEILLANCE; 11.5 REMARKS; REFERENCES; 12
- Nilotinib; 12.1 MECHANISM OF ACTION; 12.2 ADVERSE EVENTS; 12.3 OFF-LABEL EXPERIENCE; 12.4 POSTMARKETING SURVEILLANCE; 12.5 REMARKS; REFERENCES; 13
- Pazopanib.
- 13.1 MECHANISM OF ACTION13.2 ADVERSE EVENTS; 13.3 OFF-LABEL EXPERIENCE; 13.4 POSTMARKETING SURVEILLANCE; 13.5 REMARKS; REFERENCES; 14
- Vandetanib; 14.1 MECHANISM OF ACTION; 14.2 ADVERSE EVENTS; 14.3 OFF-LABEL EXPERIENCE; 14.4 POSTMARKETING SURVEILLANCE; 14.5 REMARKS; REFERENCES; 15
- Vemurafenib; 15.1 MECHANISM OF ACTION; 15.2 ADVERSE EVENTS; 15.3 OFF-LABEL EXPERIENCE; 15.4 POSTMARKETING SURVEILLANCE; 15.5 REMARKS; REFERENCES; 16
- Crizotinib; 16.1 MECHANISM OF ACTION; 16.2 ADVERSE EVENTS; 16.3 OFF-LABEL EXPERIENCE; 16.4 POSTMARKETING SURVEILLANCE; 16.5 REMARKS; REFERENCES; 17
- Ruxolitinib.
